| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 03/28/2002 | WO2002024658A2 Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists |
| 03/28/2002 | WO2002024657A2 Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists |
| 03/28/2002 | WO2002024653A1 Compounds and methods for modulation of estrogen receptors |
| 03/28/2002 | WO2002024647A1 Ep4 receptor agonists containing 8-azaprostaglandin derivatives as the active ingredient |
| 03/28/2002 | WO2002024641A1 Tricyclic indole compounds having affinity for serotonin receptor |
| 03/28/2002 | WO2002024636A2 N-acylsulfonamide apoptosis promoters |
| 03/28/2002 | WO2002024629A1 Zwitterionic tachykinin receptor antagonists |
| 03/28/2002 | WO2002024231A1 Use of a nucleic acid/pei complex |
| 03/28/2002 | WO2002024222A2 Ligands for g protein coupled receptors and methods of using them |
| 03/28/2002 | WO2002024219A1 Growth factor complex |
| 03/28/2002 | WO2002024200A1 Substituted azole derivatives as inhibitors of corticotropin releasing factor |
| 03/28/2002 | WO2002024194A2 Use of statins (hmg-coa reductase inhibitors) for the preparation of medicament as a novel type of immunomodulator, immunosuppressor and anti-inflammatory agent |
| 03/28/2002 | WO2002024192A1 Dipeptide ligands of the npff receptor for treating pain and hyperalgesia |
| 03/28/2002 | WO2002024183A1 Use of myxoxanthophyll and/or echinenone for the prophylactic and/or therapeutic treatment of undesirable physical conditions conditioned or favoured by oxidative processes |
| 03/28/2002 | WO2002024162A1 Phosphatidylserine-carrying apoptosis-mimicking bodies and the use thereof in medical treatment |
| 03/28/2002 | WO2002024158A2 Pulmonary delivery in treating disorders of the central nervous system |
| 03/28/2002 | WO2002024146A2 Methods of decreasing or preventing pain using spicamycin derivatives |
| 03/28/2002 | WO2002004624A9 Novel g protein-coupled receptor protein and dna thereof |
| 03/28/2002 | WO2001097751A3 New formulation comprising a betablocker and optionally a cholesterol-lowering agent |
| 03/28/2002 | WO2001090106A3 Tryasolyl tropane derivatives as ccr5 modulators |
| 03/28/2002 | WO2001089453A3 Derivatives of 2-aminotetralins and pharmaceutical analogs thereof exhibiting differential cns receptor activity and behavior |
| 03/28/2002 | WO2001087281A3 Method for enhancing cognitive function |
| 03/28/2002 | WO2001085781A3 Repair of nerve damage |
| 03/28/2002 | WO2001085762B1 Cancer diagnosis and assays for screening anti-cancer agents |
| 03/28/2002 | WO2001085169A3 R-eliprodil for treating glaucoma |
| 03/28/2002 | WO2001085152A3 R-eliprodil for treating glaucoma |
| 03/28/2002 | WO2001083434A3 P-(sulfonyl)-aryl and heteroaryls amines |
| 03/28/2002 | WO2001080822A3 Effervescent granules and methods for their preparation |
| 03/28/2002 | WO2001077170A3 Multiprotein-complexes comprising a nmda receptor and uses thereof |
| 03/28/2002 | WO2001076571A3 Use of sabcomeline in the treatment of anxiety |
| 03/28/2002 | WO2001066596A3 Human fgf-23 gene and gene expression products |
| 03/28/2002 | WO2001066107A3 Treatment of diseases associated with cytokine production with inhibitors of the tec family of protein tyrosine kinases |
| 03/28/2002 | WO2001064631A3 Derives de polyfluoroalkylimidazole et leur utilisation en tant qu'antagonistes des recepteur muscariniques m3 et serotoniques 5-ht4 |
| 03/28/2002 | WO2001062793A3 Estrogen receptor beta variants and methods of detection thereof |
| 03/28/2002 | WO2001055356A3 Human protein kinases and protein kinase-like enzymes |
| 03/28/2002 | WO2001049687A3 Cyclohexene nucleic acids |
| 03/28/2002 | WO2001045686A3 Formulations of adenosine a1 agonists |
| 03/28/2002 | WO2001038486A3 Kunitz-type protease inhibitor polynucleotides, polypeptides, and antibodies |
| 03/28/2002 | WO2001032216A3 Product comprising at least a no synthase inhibiting substance associated with at least a phospholipase a2 inhibiting substance |
| 03/28/2002 | WO2001023377A9 Polymorphic salt |
| 03/28/2002 | WO2001009183A3 Polymorphisms in the human mdr-1 gene and applications thereof |
| 03/28/2002 | WO2001007405A3 New vitamin d derivatives with cyclic substructures in the side chains, method and intermediates for their production and their use in the preparation of medicaments |
| 03/28/2002 | WO2000066102A3 Pentoxifylline, pioglitazone and metformin are inhibitors of formation of advanced glycation endproducts (age's) |
| 03/28/2002 | WO2000063241A9 Methods and compositions for modulating an immune response |
| 03/28/2002 | WO2000060051A3 Arpe-19 as a platform cell line for encapsulated cell-based delivery |
| 03/28/2002 | WO2000048621A9 Methods and compositions for regulating protein-protein interactions |
| 03/28/2002 | US20020038030 For therapy of inflammatory conditions including migraine, rheumatoid arthritis, asthma, and inflammatory bowel disease as well as mediation of the emetic reflex and the modulation of central nervous system (CNS) disorders such as Parkinson's |
| 03/28/2002 | US20020038028 For therapy of neurological and psychological disorders are claimed. |
| 03/28/2002 | US20020038002 To suppress immune system for therapy of symptoms associated with immune disorders such as allergies, transplanted tissue rejection and autoimmune diabetes, rheumatoid arthritis and multiple sclerosis |
| 03/28/2002 | US20020037931 Treating mood disorders, Parkinson's disease, disorders of the gastrointestinal system, edema formation states and hypertension; for example, 6,7-dihydroxy-8-nitro-3,4-dihydro-2H-naphthalen-1-one |
| 03/28/2002 | US20020037927 Halogenated 2-amino-4, 5 heptenoic acid derivatives useful as nitric oxide synthase inhibitors |
| 03/28/2002 | US20020037926 And gabapentin and/or pregabalin or their salts to prevent or ameliorate chronic pain or convulsions; synergistic |
| 03/28/2002 | US20020037925 By administering a drug that increases central nervous system GABA (4-aminobutyric acid) levels; for example gabapentin, valproic acid, progabide, gamma- hydroxybutyric acid, fengabine, cetylGABA, topiramate, tiagabine, or acamprosate |
| 03/28/2002 | US20020037919 Compositions and methods of paclitaxel for preventing psoriasis |
| 03/28/2002 | US20020037915 4-(4-(1- phenyl-5-propylpyrazol4-yl)(1,3-thiazol-2-yl))-5-methylthiothiophene-2 -carboxamidine, for example; complement inhibitors; treating tissue damage, inflammation, or autoimmune diseases |
| 03/28/2002 | US20020037909 Enamine derivatives |
| 03/28/2002 | US20020037904 Substituted 4,9-dihydrocyclopent a [imn] phenanthridine-5-ones, derivatives thereof and their uses |
| 03/28/2002 | US20020037900 Hydroxamic acid derivatives |
| 03/28/2002 | US20020037896 Bicyclic compounds |
| 03/28/2002 | US20020037895 Wherein the lactone ring is modified; preventing or treating disorders or diseases mediated by LFA-1 (Leukocyte Function-associated Antigen-1) ICAM-1 (intercellular adhesion molecules) interactions; autoimmune disorders, inflammation |
| 03/28/2002 | US20020037894 5,5-dioxo-2,3,3a,4-tetrahydro-1 H-pyrrolo(2,1-c)(1,2,4)-benzothiadiazin-7-ol, for example; nervous system disorders; alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA) modulators |
| 03/28/2002 | US20020037893 Heteroaryl diazabicycloalkanes, their preparation and use |
| 03/28/2002 | US20020037892 Bis-arylsulfones |
| 03/28/2002 | US20020037886 Muscarinic agonists |
| 03/28/2002 | US20020037878 Prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives |
| 03/28/2002 | US20020037872 N6 heterocyclic 5' modified adenosine derivatives |
| 03/28/2002 | US20020037866 Pharmaceutical composition comprising antisense-nucleic acid for prevention and/or treatment of neuronal injury, degeneration and cell death and for the treatment of neoplasms |
| 03/28/2002 | US20020037850 Genetic engineering; binding to antibodies |
| 03/28/2002 | US20020037848 Alzheimer's disease; Parkinson's disease |
| 03/28/2002 | US20020037843 Method and composition for modulating amyloidosis |
| 03/28/2002 | US20020037549 ABC transport polynucleotides, polypeptides, and antibodies |
| 03/28/2002 | US20020037533 A compound that is a Prolactin Releasing Peptide receptor (PrRP) agonist; determining the ability of the compound to promote wakefulness; providing a PrRP receptor antagonist and determining the ability of the compound to promote sleep |
| 03/28/2002 | US20020037524 Nucleotide sequences for use in diagnosis, treatment and prevention of cancer, inflammation, autoimmune disease and infections |
| 03/28/2002 | US20020037523 Nucleotide sequences coding polypeptide for use in the diagnosis, treatment and prevention of nervous system, autoimmune, inflammation, glomerulonephritis and osteoporosis disorders |
| 03/28/2002 | US20020037515 Nucleotide sequences which code a membrane protein for use in flavor intensification of in food, beverages or pharmaceuticals |
| 03/28/2002 | US20020037491 Oral transmucosal delivery |
| 03/28/2002 | US20020037281 Methods of transducing neural cells using lentivirus vectors |
| 03/28/2002 | DE10139115A1 Citalopram enthaltende pharmazeutische Zusammensetzung Citalopram pharmaceutical composition containing |
| 03/28/2002 | DE10043457A1 Verfahren zur Behandlung von Schizophrenie und verwandten Psychosen sowie Verwendung von Erythropoietin oder Erythropoietinderivaten zur Behandlung von Schizophrenien und verwandten Psychosen A method for the treatment of schizophrenia and related psychoses, and the use of erythropoietin for the treatment or Erythropoietinderivaten of schizophrenia and related psychoses |
| 03/28/2002 | DE10043321A1 Transdermales therapeutisches System Transdermal therapeutic system |
| 03/28/2002 | DE10042412A1 Transdermal patch for administering venlafaxin, useful for prophylaxis or therapy of psychoses, especially depression, as well as anxiety, neuroses and psychopathies |
| 03/28/2002 | CA2424394A1 Growth factor complex comprising an insulin-like growth factor binding protein bound to vitronectin |
| 03/28/2002 | CA2423703A1 Use of a nucleic acid/pei complex |
| 03/28/2002 | CA2423356A1 Zwitterionic tachykinin receptor antagonists |
| 03/28/2002 | CA2423284A1 Octahydro-indolizines and quinolizines and hexahydro-pyrrolizines |
| 03/28/2002 | CA2423156A1 Substituted azole derivatives as inhibitors of corticotropin releasing factor |
| 03/28/2002 | CA2423154A1 Imidazole derivatives as raf kinase inhibitors |
| 03/28/2002 | CA2423106A1 Compounds and methods for modulation of estrogen receptors |
| 03/28/2002 | CA2423104A1 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof |
| 03/28/2002 | CA2423071A1 Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
| 03/28/2002 | CA2423058A1 Polypeptide having phospholipase a2 activity |
| 03/28/2002 | CA2422911A1 New inhibitors of iapp fibril formation and uses thereof |
| 03/28/2002 | CA2422820A1 Use of statins (hmg-coa reductase inhibitors) for the preparation of medicament as a novel type of immunomodulator, immunosuppressor and anti-inflammatory agent |
| 03/28/2002 | CA2422686A1 Phosphatidylserine-carrying apoptosis-mimicking bodies and the use thereof in medical treatment |
| 03/28/2002 | CA2422215A1 B7-like molecules and uses thereof |
| 03/28/2002 | CA2421869A1 Tetrahydrofuran derivatives and their use as nk-1 antagonists |
| 03/28/2002 | CA2421865A1 Olfactory and pheromones g-protein coupled receptors |
| 03/28/2002 | CA2421823A1 Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists |
| 03/28/2002 | CA2421485A1 Water soluble rapamycin esters |
| 03/28/2002 | CA2420862A1 Protein phosphatases |